SRTS vs STXS

For growth investors, Stereotaxis, Inc.

(STXS) is the stronger pick with 0. 5% revenue growth year-over-year, versus -34. 3% for Sensus Healthcare, Inc. (SRTS). Analysts rate Stereotaxis, Inc. (STXS) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Sensus Healthcare, Inc.

(SRTS) delivered a total return of +20. 9%, compared to -71. 6% for Stereotaxis, Inc. (STXS). Over 10 years, the gap is even starker: STXS returned +25. 0% versus SRTS's -29. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Sensus Healthcare, Inc.

(SRTS) is the lower-risk stock at 0. 93β versus Stereotaxis, Inc. 's 1. 73β — meaning STXS is approximately 85% more volatile than SRTS relative to the S&P 500. On balance sheet safety, Sensus Healthcare, Inc. (SRTS) carries a lower debt/equity ratio of 1% versus 53% for Stereotaxis, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Stereotaxis, Inc.

(STXS) is pulling ahead at 0. 5% versus -34. 3% for Sensus Healthcare, Inc. (SRTS). On earnings-per-share growth, the picture is similar: Stereotaxis, Inc. grew EPS -11. 1% year-over-year, compared to -214. 6% for Sensus Healthcare, Inc.. Over a 3-year CAGR, STXS leads at -8. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Sensus Healthcare, Inc.

(SRTS) is the more profitable company, earning -28. 1% net margin versus -89. 3% for Stereotaxis, Inc. — meaning it keeps -28. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SRTS leads at -37. 5% versus -91. 9% for STXS. At the gross margin level — before operating expenses — STXS leads at 54. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Sensus Healthcare, Inc.

(SRTS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 93)). Stereotaxis, Inc. (STXS) carries a higher beta of 1. 73 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SRTS: -29. 7%, STXS: +25. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.